Oarsman Capital’s ResMed RMD Stock Holding History

Oarsman Capital’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-40	Closed	-$9.15K	–	701
2024 Q4	$9.15K	Hold	40	–	–	﹤0.01%	704
2024 Q3	$9.77K	Buy	+40	New	+$8.94K	﹤0.01%	708

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Oarsman Capital's RMD Position: Q1 2025 in Review

Oarsman Capital sold out of ResMed (RMD) in Q1 2025, closing a stake of 40 shares — an estimated $9.15K sold.

Oarsman Capital first reported a position in RMD in Q3 2024 and held it in 2 quarters. The position peaked at $9.77K in Q3 2024. 885 funds tracked by Wall St. Rank hold RMD as of Q1 2025.

Oarsman Capital reported no remaining ResMed position as of Q1 2025 after selling out during the quarter.
Oarsman Capital sold 40 ResMed shares in Q1 2025, an estimated $9.15K.
Oarsman Capital first reported a position in ResMed in Q3 2024 and held it in 2 quarters.
Oarsman Capital's ResMed position peaked at $9.77K in Q3 2024.
885 funds tracked by Wall St. Rank held ResMed as of Q1 2025.

Based on Oarsman Capital's 13F filing for Q1 2025, filed 14 May 2025.